Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-28
2008-09-16
Robinson, Hope A (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C435S007100
Reexamination Certificate
active
07425539
ABSTRACT:
The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The Factor IXa can be produced by proteolytically activating recombinantly-produced Factor IX. The invention also provides an improved method for producing Factor IXa from a plasma fraction, which method results in a Factor IXa product containing little or no prekallikrein activity, thus reducing the incidence of undesired side effects in a subject.
REFERENCES:
patent: 3560475 (1971-02-01), Fekete et al.
patent: 4286056 (1981-08-01), Andary et al.
patent: 4357321 (1982-11-01), Thomas
patent: 4770999 (1988-09-01), Kaufmann et al.
patent: 5171569 (1992-12-01), Anson et al.
patent: 5457181 (1995-10-01), Michalski et al.
patent: 5770700 (1998-06-01), Webb et al.
patent: 5919909 (1999-07-01), Josic et al.
patent: 6037452 (2000-03-01), Minamino et al.
patent: 6586573 (2003-07-01), Bresman et al.
patent: 6624289 (2003-09-01), Bajaj
patent: 6649386 (2003-11-01), Roser
patent: 7087723 (2006-08-01), Bresman et al.
patent: 7247707 (2007-07-01), Bresman et al.
patent: 2003/0050225 (2003-03-01), Butenas et al.
patent: 2003/0203845 (2003-10-01), Knudsen et al.
patent: 2004/0023333 (2004-02-01), Hauser et al.
patent: 2004/0072757 (2004-04-01), Wolf et al.
patent: 2004/0110675 (2004-06-01), Sheehan
patent: 2004/0235737 (2004-11-01), Barrowcliffe
patent: 1 048 735 (2000-11-01), None
patent: 1 260 582 (2004-11-01), None
patent: 1635861 (2006-03-01), None
patent: WO96/00577 (1996-01-01), None
patent: WO 2004/103397 (2004-12-01), None
Ahmad, S.S., et al.; “The Role of the Second Growth-Factor Domain of Human Factor IXa in Binding to Platelets and in Factor-X Activation”;Biochemical Journal; 310; pp. 427-431 (1995).
Astermark, J.; “Treatment of the Bleeding Inhibitor Patient”;Semin Thromb Hemost; 29(1); pp. 77-86 (2003).
Bajaj, S.P.; “Region of Factor IXa Protease Domain that Interacts with Factor Villa: Analysis of Select Hemophilia B Mutants”;Thrombosis&Haemostasis; 82(2): pp. 218-225 (1999).
Bajaj, S.P., et al.; “Factor IXa:Factor Villa Interaction”;Journal of Biological Chemistry; 276(19); pp. 16302-16309 (2001).
Choo, K.H., et al.; “Molecular Cloning of the Gene for Human Anti-Haemophilic Factor IX”;Nature; 299; pp. 178-180 (1982).
Dusel, C.H., et al.; “Identification of Prothrombin as a Major Thrombogenic Agent in Prothrombin Complex Concentrates”;Blood Coagulation and Fibrinolysis; vol. 15, No. 5; pp. 405-411 (2004).
Fair, et al.; “Human Hepatoma Cells Secrete Single Chain Factor X, Prothrombin, and Antithrombin III”;Blood; 64(1):194-204 (1984).
Fuchs, H.E., et al,; “Regulation of Factor IXaIn Vitro in Human and Mouse Plasma and in Vivo in the Mouse”;J. Clin. Invest.; vol. 73, pp. 1696-1703 (1984).
Gallisti, S., et al.; “Respective Roles of Factors II, VII, IX, and X in the Procoagulant Activity of FEIBA”;Blood Coagul Fibrinolysis; vol. 13(7); pp. 653-655 (2002).
Gray, E., et al.; “Measurement of Activated Factor IX in Factor IX Concentrates; Correlation with in Vivo Thrombogenicity”;Thrombosis&Haemostasis; 3(4); pp. 675-679 (1995).
Hellstern, P.; “Production and Composition of Prothrombin Complex Concentrates: Correlation Between Composition and Therapeutic Efficiency”;Thromb. Res.; Vo. 95(4 Suppl 1); pp. S7-12 (1999).
Himmelspach, M., et al.; “A Fully Recombinant Partial Prothrombin Complex Effectively Bypasses fVIII in vitro and in vivo”;Thromb. Haemost.; vol. 88(6); pp. 1003-1011 (2002).
Kurachi, et al.; “Isolation and Characterization of a cDNA Coding for Human Factor IX”;Proc. Natl. Acad. Sci. USA; 79:6461-6464 (1982).
Kusch, M., et al.; “High Sensitivity Detection of Activated Factor IX”;Thromb. Haemost.; vol. 79(4); pp. 778-783 (1998).
Lowe, G.D.; “Factor IX and Thrombosis”;Br. J. Haematol.; vol. 115(3); pp. 507-513 (2001).
Lundblad, R.L., et al.; “Measurement of Active Coagulation Factors in Autoplex-T with Colorimetric Active Site-Specific Assay Technology”;Thrombosis&Haemostasis; 80; pp. 811-815 (1998).
McNeely, T.B., et al.; “The Anticoagulant Mechanism of Action of Heparin in Contact-Activated Plasma: Inhibition of Factor X Activation”;Blood; vol. 65, No. 5; pp. 1226-1231 (1985).
Nemerson, Y; “Tissue Factor and Hemostasis”;Blood; vol. 71:1, pp. 1-8 (1988).
Philippou, H., et al.; “High Purity Factor IX and Prothrombin Complex Concentrate (PCC): Pharmacokinetics and Evidence that Factor IXa is the Thrombogenic Trigger in PCC”;Thrombosis&Haemostasis; l76(1): pp. 23-28 (1996).
Pieters, J., et al.; “Heparin-Stimulated Inhibition of Factor IXa Generation and Faxtor IXa Neutralization in Plasma”;Blood; vol. 76:3; pp. 549-554 (1990).
Shord, S.S., et al,; “Coagulation Products and Their Uses”;Am. J. Health-Syst. Pharm; vol. 57; pp. 1403-1417 (2000).
Tankersley, et al,; “Activation of Factor XII by Dextran Sulfate: The Basis for an Assay of Factor XII”;Blood; 62(2):448-456 (1983).
Van Dieijen, G., et al.; “The Role of Phospholipid and Factor Villa in the Activation of Bovine Factor X”;J Biol Chem.; 256:7; pp. 3433-3442 (1981).
Wojcik, E.G.C., et al.; “Modification of the N-Terminus of Human Factor IX by Defective Propeptide Cleavage or Acetylation Results in a Destabilized Calcium-Induced Conformation: Effects on Phospholipid Binding and Activation by Factor XIa”;Biochem J; 323; pp. 629-636 (1997).
Zhong, D., et al.; “First Epidermal Growth Factor-Like Domain of Human Blood Coagulation Factor IX is Required for its Activation by Factor Vlla/ Tissue Factor but not by Factor Xia”;Proc. Natl. Acad. Sci. USA; vol. 91; pp. 3574-3578 (1994).
Barrowcliffe, T.W., et al.; “Binding to Phospholipid Protects Factor-VIII from Inactivation by Human Antibodies”;Journal of Laboratory and Clinical Medicine; vol. 101, No. 1, pp. 34-43 (1983).
S. Schulman,Protein Content of Coagulation Factor Concentrates, “Biotechnology and the Promise of Pure Factor VIII”—Proceedings of the Symposium on Biotechnology and the Promise of Pure FVIII, 1988, Monte-Carlo, pp. 21-30.
Royal A. Mccgraw et al., “Structure and Function of Factor IX: Defects in Haemophilia B”,Clin Haematol, 1985, pp. 359-383, vol. 14, Issue 2.
Baker Donald A.
Donovan Shane
Baxter Healthcare S.A.
Baxter International Inc.
LandOfFree
Factor IXa for the treatment of bleeding disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Factor IXa for the treatment of bleeding disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor IXa for the treatment of bleeding disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3972159